COVID-19 Update: We are currently shipping orders daily. However, due to transit disruptions in some geographies, deliveries may be delayed. To provide all customers with timely access to content, we are offering 50% off Science and Technology Print & eBook bundle options. Terms & conditions.
Progress in Medicinal Chemistry - 1st Edition - ISBN: 9780444639394, 9780444639431

Progress in Medicinal Chemistry, Volume 56

1st Edition

Serial Editors: David R. Witty Brian Cox
Hardcover ISBN: 9780444639394
eBook ISBN: 9780444639431
Imprint: Elsevier
Published Date: 15th March 2017
Page Count: 174
Sales tax will be calculated at check-out Price includes VAT/GST
Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

Chapter One: Enabling Chemistry Technologies and Parallel Synthesis—Accelerators of Drug Discovery Programmes

  • Abstract
  • 1 Introduction
  • 2 The Evolution of Flow-Based Approaches to Synthesis
  • 3 Use of High-Temperature Chemistries
  • 4 Use of Photochemical and Electrochemical Reactions
  • 5 Use of Hazardous Gases (e.g. Diazomethane) in Flow
  • 6 Library Design Tools and Processes
  • 7 Use of Flow Chemistry for Library Synthesis
  • 8 Summary and Future Perspectives
  • Acknowledgements

Chapter Two: Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease

  • Abstract
  • 1 Introduction
  • 2 LRRK2 Biology
  • 3 Structural Biology of LRRK2
  • 4 Overview of Selective Inhibitors of LRRK2
  • 5 Conclusion

Chapter Three: Recent Progress in the Discovery and Development of TRPA1 Modulators

  • Abstract
  • 1 TRPA1: An Introduction
  • 2 Validation as a Target for Drug Discovery
  • 3 Medicinal Chemistry and Clinical Status of TRPA1 Modulators
  • 4 Recent Structural Insights
  • 5 Conclusions and Outlook

Chapter Four: Small Molecule Inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4)

  • Abstract
  • 1 Introduction
  • 2 Small Molecule IRAK4 Inhibitor Discovery
  • 3 Summary of Clinical Status
  • 4 Conclusion


Progress in Medicinal Chemistry, Volume 56 provides a review of eclectic developments in medicinal chemistry. This volume includes chapters covering recent advances in cancer therapeutics, fluorine in medicinal chemistry, a perspective on the next generation of antibacterial agents derived by manipulation of natural products, a potential new era for Chagas Disease drug discovery, and imaging in drug development. Specific chapters cover timely topics, such as the development of LRRK2 inhibitors for the treatment of Parkinson's, and recent discoveries and developments in TRPA1 modulators.

Users will find a comprehensive resource on the topic of medicinal chemistry that also discusses avenues for the acceleration of drug discovery programs.

Key Features

  • Extended, timely reviews of topics in medicinal chemistry
  • Contains targets and technologies relevant to the discovery of tomorrow’s drugs
  • Presents analyses of successful drug discovery programs


Everyone interested in the strategy and practice of the preclinical phases of the creation of new medicines. Those wishing to understand the drivers of drug design or expand their knowledge of therapeutic target classes


No. of pages:
© Elsevier 2017
15th March 2017
Hardcover ISBN:
eBook ISBN:

Ratings and Reviews

About the Serial Editors

David R. Witty

David R. Witty

Dr David Witty has more than 20 years experience in the pharmaceutical industry as a medicinal chemist and project leader working principally in areas of anti-infectives, metabolic diseases, cognition and pain, delivering clinical candidates for several conditions. He led IT Strategy within the Neurology division of GSK, developing and deploying the first Electronic Notebooks for drug discovery to sites in the UK and Singapore. He has contributed more than 90 scientific papers, reviews, patents and books on medicinal and synthetic chemistry.

In 2010 David and several colleagues successfully raised $35M in venture funding to found Convergence Pharmaceuticals, a specialist ion channel company focused on the development of novel treatments for pain, based in Cambridge UK. David presently leads their discovery programme and manages scientific operations within the business.

David is chairman of the Fine Chemicals Group of the Society of Chemical Industry, with responsibility for the delivery of conferences, seminars and training courses for chemists throughout the UK and Europe, and advising parliamentary bodies on matters of relevance to the UK chemical industry.

Since 2008 David has been a STEM ambassador for SETPOINT, introducing school students at both primary and secondary level to the excitement and possibilities of pursuing scientific careers, through workshops, lectures and competitions.

Affiliations and Expertise

WITNET LTD, Cambridge, UK

Brian Cox

Professor Brian Cox is at University of Sussex, Brighton, UK

Affiliations and Expertise

University of Sussex, Brighton, UK